Dr. Betty Pace, MD

NPI: 1700195039
Total Payments
$42,018
2024 Payments
$18,047
Companies
6
Transactions
27

Payment Breakdown by Category

Consulting$41,120 (97.9%)
Food & Beverage$493.84 (1.2%)
Travel$405.06 (1.0%)
Other$0.00 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $41,120 13 97.9%
Food and Beverage $493.84 11 1.2%
Travel and Lodging $405.06 3 1.0%

Top Paying Companies

Company Total Records Latest Year
PFIZER INC. $25,035 10 $0 (2024)
Novo Nordisk Health Care AG $10,710 2 $0 (2024)
Novartis Pharmaceuticals Corporation $6,052 8 $0 (2019)
Global Blood Therapeutics, Inc. $170.24 5 $0 (2022)
CSL Behring $28.83 1 $0 (2017)
Novo Nordisk Inc $23.19 1 $0 (2019)

Payment History by Year

Year Amount Transactions Top Company
2024 $18,047 6 PFIZER INC. ($13,287)
2023 $17,698 6 PFIZER INC. ($11,748)
2022 $18.05 1 Global Blood Therapeutics, Inc. ($18.05)
2021 $139.74 3 Global Blood Therapeutics, Inc. ($139.74)
2020 $12.45 1 Global Blood Therapeutics, Inc. ($12.45)
2019 $169.27 3 Novartis Pharmaceuticals Corporation ($146.08)
2018 $5,906 6 Novartis Pharmaceuticals Corporation ($5,906)
2017 $28.83 1 CSL Behring ($28.83)

All Payment Transactions

27 individual payment records from CMS Open Payments — Page 1 of 2

Date Company Product Nature Form Amount Type
11/12/2024 PFIZER INC. Consulting Fee Cash or cash equivalent $2,937.00 General
07/29/2024 PFIZER INC. Consulting Fee Cash or cash equivalent $3,055.00 General
07/29/2024 PFIZER INC. Consulting Fee Cash or cash equivalent $2,467.00 General
05/28/2024 PFIZER INC. Consulting Fee Cash or cash equivalent $3,417.50 General
05/28/2024 PFIZER INC. Consulting Fee Cash or cash equivalent $1,410.00 General
01/08/2024 Novo Nordisk Health Care AG Consulting Fee Cash or cash equivalent $4,760.00 General
12/26/2023 PFIZER INC. Consulting Fee Cash or cash equivalent $4,464.00 General
11/20/2023 PFIZER INC. Consulting Fee Cash or cash equivalent $2,467.00 General
10/30/2023 Novo Nordisk Health Care AG Consulting Fee Cash or cash equivalent $5,950.00 General
09/28/2023 PFIZER INC. Consulting Fee Cash or cash equivalent $1,527.00 General
08/28/2023 PFIZER INC. Consulting Fee Cash or cash equivalent $2,115.00 General
05/22/2023 PFIZER INC. Consulting Fee Cash or cash equivalent $1,175.00 General
02/15/2022 Global Blood Therapeutics, Inc. OXBRYTA (Drug) Food and Beverage In-kind items and services $18.05 General
Category: Sickle Cell Disease
12/11/2021 Global Blood Therapeutics, Inc. OXBRYTA (Drug) Food and Beverage In-kind items and services $103.40 General
Category: SICKLE CELL DISEASE
04/15/2021 Global Blood Therapeutics, Inc. OXBRYTA (Drug) Food and Beverage In-kind items and services $12.38 General
Category: SICKLE CELL DISEASE
03/25/2021 Global Blood Therapeutics, Inc. OXBRYTA (Drug) Food and Beverage In-kind items and services $23.96 General
Category: SICKLE CELL DISEASE
11/19/2020 Global Blood Therapeutics, Inc. OXBRYTA (Drug) Food and Beverage In-kind items and services $12.45 General
Category: SICKLE CELL DISEASE
11/25/2019 Novartis Pharmaceuticals Corporation Food and Beverage In-kind items and services $22.84 General
08/27/2019 Novartis Pharmaceuticals Corporation PROMACTA (Drug) Food and Beverage In-kind items and services $123.24 General
Category: ONCOLOGY
07/03/2019 Novo Nordisk Inc Novoeight (Drug), REBINYN Food and Beverage In-kind items and services $23.19 General
Category: Hemophilia
05/19/2018 Novartis Pharmaceuticals Corporation CRIZANLIZUMAB (Biological) Consulting Fee Cash or cash equivalent $5,375.00 General
05/19/2018 Novartis Pharmaceuticals Corporation CRIZANLIZUMAB (Biological) Travel and Lodging In-kind items and services $202.56 General
05/19/2018 Novartis Pharmaceuticals Corporation CRIZANLIZUMAB (Biological) Travel and Lodging Cash or cash equivalent $163.50 General
05/19/2018 Novartis Pharmaceuticals Corporation CRIZANLIZUMAB (Biological) Food and Beverage In-kind items and services $107.14 General
05/19/2018 Novartis Pharmaceuticals Corporation CRIZANLIZUMAB (Biological) Travel and Lodging Cash or cash equivalent $39.00 General

About Dr. Betty Pace, MD

Dr. Betty Pace, MD is a Pediatric Hematology-Oncology healthcare provider based in Augusta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/05/2010. The National Provider Identifier (NPI) number assigned to this provider is 1700195039.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Betty Pace, MD has received a total of $42,018 in payments from pharmaceutical and medical device companies, with $18,047 received in 2024. These payments were reported across 27 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($41,120).

Practice Information

  • Specialty Pediatric Hematology-Oncology
  • Location Augusta, GA
  • Active Since 10/05/2010
  • Last Updated 10/05/2010
  • Taxonomy Code 2080P0207X
  • Entity Type Individual
  • NPI Number 1700195039

Products in Payments

  • CRIZANLIZUMAB (Biological) $5,887
  • OXBRYTA (Drug) $170.24
  • PROMACTA (Drug) $141.60
  • Afstyla (Biological) $28.83
  • Novoeight (Drug) $23.19

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatric Hematology-Oncology Doctors in Augusta